ECP 2023 Final Programme

Poster Sessions a Tuesday 97 ECP 2023 Dublin Tuesday, 12 Sept PS-17 002 Does the morphology of Helicobacter pylori matters for the histopathology in gastric endoscopic biopsies? Yasemen Adali, Turkey Ö. Ertener, H. Beşeren, G. Yıldız 003 Clinicopathological spectrum of primary anorectal melanoma: a single centre experience of 36 resected cases Tushar Agrawal, India M. Bal, K. Deodhar, M. Ramadwar, A. Saklani, S. Yadav, R. Kumar 004 TempO-Seq Detects Fusobacterium nucleatum in formalin-fixed paraffin-em- bedded patient tissue from a bowel screening population Sara Samir Foad Al-Badran, United Kingdom S. McSorley, M. Johnstone, J. Hay, J. Jawny, N. Maka, D. Andersen, G. Lynch, J. Edwards 005 Immunohistochemical assessment of Ki67 and pathway analysis in pre-malignant colonic polyps suggest Ki67 as a potential prognostic maker for metachronous disease Aula Ammar, United Kingdom 006 Dysplasia in sessile serrated lesions: prevalence, interobserver variability and value of immunohistochemistry Valentina Angerilli, The Netherlands M. Vink-Börger, G. van Lijnschoten, N. van Grieken, M. Fassan, R. van der Post, I. Nagtegaal 007 Early-onset small bowel adenocarcinomas (EO-SBAs) are more frequently associated with a predisposing condition compared to late-onset SBAs: an international multi- center study Giovanni Arpa, Italy C. Guerini, M. Lenti, E. Quaquarini, F. Grillo, F. Antoci, E. Travaglino, M. Fassan, R. Graham, A. Casadei Gardini, M. Ferrante, A. Moens, G. De Hertog, A. Di Sabatino, A. Vanoli 008 Mucinous carcinoma: pathomolecular and microenvironment characterisation – a trans organ study Mohamed Amine Bani, France P. Dartigues, C. Genestie, M. Classe, A. Boileve, M. Ducreux, J. Scoazec 009 Small intestinal metaplasia in indefinite for dysplasia, dysplasia, and adenocarcinoma in patients with inflammatory bowel disease Armando Del Portillo, USA A. Koehne de Gonzalez, L. Fazlollahi 010 Prognostic value of tumour infiltrating lymphocytes in colon cancer Sarra Gharbi, France D. Bacha, I. Mallek, E. Benammou, M. Hajri, H. Mestiri, A. Lahmar, S. Ben Slama 011 In-house validated approach of gastric cancer: a tool for a better evaluation of HER2 heterogeneity Simona Gurzu, Romania C. Satala, Z. Kovacs, I. Jung 012 IL-17-positive cells in gastric cancer Mehmed Hadzhi, Bulgaria P. Petkova, K. Dinkova, M. Gulubova 013 Ki67 is a good prognosis marker in colorectal carcinoma Sana Hidouri, Tunisia M. Walha, D. Jamai, S. Aloulou, A. Khabir, K. Bel Hadj Ali, M. Hamdani 014 Cyclin D1 is a good prognostic biomarker in colorectal carcinoma Sana Hidouri, Tunisia M. Walha, D. Jamai, S. Aloulou, K. Bel Hadj Ali, A. Khabir, M. Hamdani 015 Oesophageal adenocarcinoma heterogenei- ty in clinicopathology and prognosis: a single-centre longitudinal cohort study of 146 patients over a 20-year period Qin Huang, USA E. Lew, Y. Cheng, S. Shinagare, V. Deshpande, D. Wiener, J. Gold, H. Weber